Blood
Blood
Audio Summaries
Every issue of Blood moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Recent summaries
The latest articles summarized from Blood.
Endothelial IDO1 Drives BBB Disruption in CAR-T-Associated Neurotoxicity Through KYNU-AA-Wnt/β-catenin Pathway.
Nov 18, 2026
This study asks how CAR-T-associated inflammation leads to blood-brain barrier (BBB) breakdown and neurotoxicity (ICANS), a mechanism that has remained poorly understood. The authors found that IDO1 activity was elevated in ICANS patients and in a CAR-T mouse model, and that IDO1 in brain endothelial cells drove barrier loss by shifting kynurenine metabolism toward KYNU-derived anthranilic acid, which suppresses Wnt/β-catenin-dependent tight junction maintenance. Pharmacological inhibition or endothelial-specific silencing of IDO1 restored barrier integrity and improved neurological outcomes, suggesting endothelial IDO1 as a therapeutic target for CAR-T neurotoxicity.
Cytokines to modulate CAR T cells.
Nov 17, 2026
This review examines how cytokines can be built into CAR T cells to overcome poor expansion, persistence, T-cell exhaustion, and immunosuppressive tumor microenvironments that limit current therapy. It traces the progression from early IL-12 approaches (which showed potent local inflammatory activity but risked systemic toxicity) through common γ-chain cytokines (IL-7, IL-15, IL-21) and IL-18, which has shown early clinical activity in hematologic malignancies. The authors conclude that rational cytokine selection for specific disease settings, combined with precise spatial and temporal control via inducible circuits and synthetic receptors, will be needed to balance efficacy against toxicity.
Microbiota-derived short-chain fatty acids control cGVHD development by regulating antibody production.
Nov 16, 2026
Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity after allogeneic stem cell transplantation, and prior work linked low circulating short-chain fatty acids (SCFAs) to higher cGVHD risk. This study asked whether SCFAs act as systemic immunomodulators that protect against cGVHD, and found that systemic butyrate or propionate treatment in mice reduced cGVHD severity and improved survival. The protective effect was associated with fewer pathogenic hyperexpanded B cells, lower recipient-specific IgA, and a reduced total alloantibody pool, pointing to antibody regulation as a mechanism linking the microbiome to cGVHD.
Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody.
Nov 16, 2026
This pooled analysis of phase 1 and phase 1b (Arm A) studies asks whether etentamig, a BCMA x CD3 bispecific T-cell engager with a low-affinity CD3 binder and FcRn-retained design, can deliver durable efficacy with a manageable safety profile and monthly dosing in heavily pretreated relapsed/refractory multiple myeloma. Among 146 patients with a median of 4 prior lines of therapy, objective response was 66% (≥VGPR 54%), with response duration and PFS not reached at a median follow-up of 13 months. Overall CRS was 30% (almost all Grade 1) with modified dexamethasone premedication and a single step-up dose, suggesting the design may reduce cytokine toxicity while supporting extended Q4W dosing.
Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial.
Nov 16, 2026
The FORTE phase 2 trial asked whether carfilzomib-based induction followed by autologous stem cell transplantation (KRd-ASCT) and carfilzomib-lenalidomide maintenance (KR) improve long-term outcomes in transplant-eligible newly diagnosed multiple myeloma. With a median follow-up of about 8 years, KRd-ASCT significantly extended progression-free survival compared with KRd alone for 12 cycles or KCd-ASCT (median PFS 98 vs 70 and 67 months), and KR maintenance improved PFS versus lenalidomide alone, with MRD negativity linked to prolonged benefit. The authors conclude that these long-term results confirm the high effectiveness of KRd-ASCT followed by KR maintenance, with a second primary malignancy incidence of 6%.
Regenerative Stress Contributes to Higher Clonal Hematopoiesis with Myelodysplastic Features in Sickle Cell Disease Mice.
Nov 16, 2026
Sickle cell disease (SCD) patients are living longer and face a rising risk of hematologic malignancy, including after gene therapy or transplant, but the underlying mechanism has been unclear. Using humanized SCD mice compared with matched controls, the authors tracked hematopoiesis through 1 year of age and deep-sequenced 450 myeloid malignancy-associated genes to test whether chronic erythropoietic demand or serial autologous transplantation (regenerative stress) drives clonal hematopoiesis. They found that SCD mice showed premature, aging-like myeloid bias, a higher frequency of dysplastic MDS-like features, and greater clonal burden, which was further amplified by serial transplantation, suggesting that early curative therapy might reduce this malignancy risk.
CENTRAL NERVOUS SYSTEM GRAFT VERSUS HOST DISEASE PATHOPHYSIOLOGY: MECHANISTIC PATHWAYS AND THERAPEUTIC TARGETS.
Nov 16, 2026
This review examines how graft-versus-host disease (GVHD) affects the central nervous system (CNS) after allogeneic stem cell transplantation, a complication associated with significant morbidity and mortality. The authors synthesize mostly murine studies to explain how disrupted vascular and lymphatic barriers allow immune cell entry into the brain, and which pathways (IL-6, TNF-α, CB2 receptor, CSF-1R, and antibiotic-induced gut dysbiosis) drive neuroinflammation. They also show that therapies effective against peripheral GVHD do not always work in the brain, underscoring the brain's distinct microenvironment and suggesting strategies to restore barrier integrity and limit T cell trafficking into the CNS.
Optimizing Reduced-Intensity Conditioning for Older Patients with AML and MDS: A Large-Scale Analysis from the CIBMTR.
Nov 13, 2026
This CIBMTR registry study asked which fludarabine-based reduced-intensity conditioning regimen best serves patients aged 50 and older with AML or MDS undergoing allogeneic transplant. Across 11,731 patients, fludarabine-melphalan regimens (100 or 140 mg/m²) had higher early mortality than fludarabine-busulfan but achieved better late overall survival, lower relapse, and improved disease-free survival in the 2019-2022 cohort. The authors conclude that fludarabine-melphalan conditioning is preferred for this older population regardless of baseline comorbidities.
CAR-T Targeting of Mutant Calreticulin Selectively Eradicates Myeloproliferative Neoplasm-Sustaining Stem Cells.
Nov 13, 2026
Myeloproliferative neoplasms driven by mutant calreticulin (CALRmut) are currently curable only with allogeneic stem cell transplantation, which also destroys healthy stem cells. This study asks whether CALRmut is consistently displayed on the surface of MPN stem cells so they can be targeted selectively. The authors developed a high-affinity CALRmut-specific CAR-T cell therapy (hAB2) that, in patient-derived xenograft models, eliminated MPN-propagating stem cells while sparing normal human and host blood cell production, supporting transplant-free immunotherapy with curative potential.
Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS.
Nov 13, 2026
This systematic analysis of MDS clinical trial publications (2015–2024) examined how key data elements and response criteria are reported, asking whether current reporting is consistent enough to allow accurate interpretation and comparison of results. The authors found substantial gaps and variability, such as baseline ANC reported in only 16–23% of trials and six to seven competing definitions of transfusion independence and overall response rate. They then used a modified-Delphi consensus process within the International Consortium for MDS to propose standardized reporting recommendations intended as benchmarks and templates for future MDS trials.
